Target intelligence / Profile preview

Protein wntless homolog (WLS)

Target
WLS
Molecular classification
Integral membrane protein, Wnt ligand secretion mediator, Cargo receptor for Wnt proteins, Other (unusual in not being a classical receptor, enzyme, or transporter)
01

Overview

Protein wntless homolog (WLS) is an integral membrane protein responsible for mediating the secretion and sorting of Wnt ligands, a family of secreted, lipid-modified signaling proteins essential for cell communication, embryonic development, and tissue homeostasis[1][3][4][5]. WLS binds Wnt proteins within the endoplasmic reticulum and facilitates their trafficking through the secretory pathway to the cell surface, enabling Wnt ligands to reach and activate their target receptors on neighboring cells[1][2][3][4]. WLS is evolutionarily conserved and indispensable for canonical and non-canonical Wnt signaling, with loss-of-function mutations implicated in developmental disorders, including Zaki syndrome[2][3][5]. While not a classical receptor, enzyme, or transporter, WLS is a critical node in the Wnt signaling pathway, making it a potential target for modulating Wnt-driven diseases—though no approved drugs directly target WLS at present.

Other names
WntlessC1orf139GPR177UNQ85/PRO18667EVIFLJ23091MRPmig-14Integral membrane protein GPR177Protein evenness interrupted homologZKS
02

Mechanism of action

Drugs (if developed) would likely inhibit or modulate WLS to disrupt Wnt ligand secretion, thereby modulating Wnt pathway signaling implicated in development and disease

03

Biological functions

Wnt-protein bindingRegulation of Wnt protein sorting and secretionProtein transportPositive regulation of cell communicationEstablishment of anterior-posterior body axis during developmentRegulation of tissue development and homeostasis
04

Disease associations

Zaki syndromeFocal dermal hypoplasiaDevelopmental disordersImplicated in tissue patterning and hair follicle induction
05

Safety considerations

Challenges targeting a broadly required developmental molecule; potential toxicity due to inhibition of normal Wnt signaling which is essential for tissue homeostasis and stem cell renewal
06

Interacting drugs

None currently approved or in advanced stages; research tools may exist but are not clinically validated
07

Biomarkers

Mutations in WLS (e.g., in congenital syndromes such as Zaki syndrome)Aberrant WLS expression may serve as a biomarker for Wnt pathway activation/disease

Beyond the preview

Go deeper on Protein wntless homolog (WLS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein wntless homolog (WLS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call